353 related articles for article (PubMed ID: 30626133)
1. Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer.
Emmings E; Mullany S; Chang Z; Landen CN; Linder S; Bazzaro M
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30626133
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Mitochondria in Ovarian Cancer Cell Metabolism, Proliferation, and Metastasis.
Schatten H
Adv Exp Med Biol; 2024; 1452():119-125. PubMed ID: 38805128
[TBL] [Abstract][Full Text] [Related]
3. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.
Sriramkumar S; Sood R; Huntington TD; Ghobashi AH; Vuong TT; Metcalfe TX; Wang W; Nephew KP; O'Hagan HM
J Transl Med; 2022 May; 20(1):246. PubMed ID: 35641987
[TBL] [Abstract][Full Text] [Related]
4. Co-targeting EGFR and Autophagy Impairs Ovarian Cancer Cell Survival during Detachment from the ECM.
Yang Z; Liu Y; Wei X; Zhou X; Gong C; Zhang T; Jin P; Xu S; Ma D; Gao Q
Curr Cancer Drug Targets; 2015; 15(3):215-26. PubMed ID: 25619386
[TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors.
Latifi A; Luwor RB; Bilandzic M; Nazaretian S; Stenvers K; Pyman J; Zhu H; Thompson EW; Quinn MA; Findlay JK; Ahmed N
PLoS One; 2012; 7(10):e46858. PubMed ID: 23056490
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells.
Han Y; Kim B; Cho U; Park IS; Kim SI; Dhanasekaran DN; Tsang BK; Song YS
Oncogene; 2019 Nov; 38(45):7089-7105. PubMed ID: 31409904
[TBL] [Abstract][Full Text] [Related]
7. Molecular characteristics and tumorigenicity of ascites-derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer.
Ding Y; Labitzky V; Legler K; Qi M; Schumacher U; Schmalfeldt B; Stürken C; Oliveira-Ferrer L
Mol Oncol; 2021 Dec; 15(12):3578-3595. PubMed ID: 34060699
[TBL] [Abstract][Full Text] [Related]
8. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells.
Alvero AB; Montagna MK; Holmberg JC; Craveiro V; Brown D; Mor G
Mol Cancer Ther; 2011 Aug; 10(8):1385-93. PubMed ID: 21677151
[TBL] [Abstract][Full Text] [Related]
9. Targeting Dormant Ovarian Cancer Cells
Huang Z; Kondoh E; Visco ZR; Baba T; Matsumura N; Dolan E; Whitaker RS; Konishi I; Fujii S; Berchuck A; Murphy SK
Mol Cancer Ther; 2021 Jan; 20(1):85-95. PubMed ID: 33037137
[TBL] [Abstract][Full Text] [Related]
10. Defects of mitochondria-lysosomes communication induce secretion of mitochondria-derived vesicles and drive chemoresistance in ovarian cancer cells.
Gagliardi S; Mitruccio M; Di Corato R; Romano R; Aloisi A; Rinaldi R; Alifano P; Guerra F; Bucci C
Cell Commun Signal; 2024 Mar; 22(1):165. PubMed ID: 38448982
[TBL] [Abstract][Full Text] [Related]
11. Adipose-derived stem cells in ovarian cancer progression, metastasis, and chemoresistance.
Zhang W; Torres-Rojas C; Yue J; Zhu BM
Exp Biol Med (Maywood); 2021 Aug; 246(16):1810-1815. PubMed ID: 34229470
[TBL] [Abstract][Full Text] [Related]
12. The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination.
Ritch SJ; Telleria CM
Front Endocrinol (Lausanne); 2022; 13():886533. PubMed ID: 35574025
[TBL] [Abstract][Full Text] [Related]
13. Adaptation of metabolism to multicellular aggregation, hypoxia and obese stromal cell incorporation as potential measure of survival of ovarian metastases.
Compton SLE; Pyne ES; Liu L; Guinan J; Shea AA; Grieco JP; Frisard MI; Schmelz EM
Exp Cell Res; 2021 Feb; 399(1):112397. PubMed ID: 33338477
[TBL] [Abstract][Full Text] [Related]
14. Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers.
Kong B; Han CY; Kim SI; Patten DA; Han Y; Carmona E; Shieh DB; Cheung AC; Mes-Masson AM; Harper ME; Song YS; Tsang BK
J Ovarian Res; 2022 Jun; 15(1):70. PubMed ID: 35668443
[TBL] [Abstract][Full Text] [Related]
15. Immobilization rapidly selects for chemoresistant ovarian cancer cells with enhanced ability to enter dormancy.
Lam T; Aguirre-Ghiso JA; Geller MA; Aksan A; Azarin SM
Biotechnol Bioeng; 2020 Oct; 117(10):3066-3080. PubMed ID: 32589792
[TBL] [Abstract][Full Text] [Related]
16. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
[TBL] [Abstract][Full Text] [Related]
17. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM
Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.
Craveiro V; Yang-Hartwich Y; Holmberg JC; Joo WD; Sumi NJ; Pizzonia J; Griffin B; Gill SK; Silasi DA; Azodi M; Rutherford T; Alvero AB; Mor G
Cancer Med; 2013 Dec; 2(6):751-62. PubMed ID: 24403249
[TBL] [Abstract][Full Text] [Related]
19. IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity.
Song M; Sandoval TA; Chae CS; Chopra S; Tan C; Rutkowski MR; Raundhal M; Chaurio RA; Payne KK; Konrad C; Bettigole SE; Shin HR; Crowley MJP; Cerliani JP; Kossenkov AV; Motorykin I; Zhang S; Manfredi G; Zamarin D; Holcomb K; Rodriguez PC; Rabinovich GA; Conejo-Garcia JR; Glimcher LH; Cubillos-Ruiz JR
Nature; 2018 Oct; 562(7727):423-428. PubMed ID: 30305738
[TBL] [Abstract][Full Text] [Related]
20. Bioenergetic analysis of ovarian cancer cell lines: profiling of histological subtypes and identification of a mitochondria-defective cell line.
Dier U; Shin DH; Hemachandra LP; Uusitalo LM; Hempel N
PLoS One; 2014; 9(5):e98479. PubMed ID: 24858344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
